1. Pink Sheet
  2. >>Market Access

Janssen May Challenge English Funding Rejection For Depression Nasal Spray

 
• By Neena Brizmohun

Health technology assessment body NICE has now rejected Spravato for the third time, saying it has concerns over the clinical evidence and economic model for the drug, for treating adults with major depression that is resistant to treatment.

Male doctor/nurse wearing blue scrubs, with a stethoscope around his neck and holding a Union Jack money purse.
NICE says Spravato would not be an acceptable use of NHS resources • Source: Alamy

Janssen says it is “considering all options including an appeal” after NICE today said that its nasal spray, Spravato(esketamine), should not be made available on the National Health Service in England for patients with treatment-resistant major depressive disorder (TRD).

The rejection by the health technology assessment institute was published on 27 May in a final appraisal document (FAD) for Spravato that is now open for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

More from Pink Sheet

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.

Blenrep’s Revival Gains Steam: EMA Decision Imminent As Japan Approves New Regimen

 
• By Neena Brizmohun

The European Medicines Agency is due to decide whether GSK’s previously approved multiple myeloma drug that was withdrawn from the market in 2022 should be approved again for use in combination with BorDex or PomDex. Meanwhile, Japan today became the second major regulator to approve the Blenrep combinations.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.